China - Re-Import of Heparin for Therapeutic Use
Since 2014, China Re-Import of Heparin for Therapeutic Use fell by 3.9% year on year. At $676,088 in 2019, the country was ranked number 3 among other countries in Re-Import of Heparin for Therapeutic Use. China is overtaken by Australia, which was number 2 with $1,253,862.5 and is followed by France at $378,030.03. Canada ranked the highest with $1,738,281.5 in 2019, a growth of 72.9% versus 2018. Australia witnessed the best average annual growth at +309.1% per year, while Thailand recorded the worst performance at -47.1% per year.
Loading...
| Date | US Dollars |
|---|---|
| 2019 | 676,088.00 |
| 2018 | 708,363.00 |
| 2017 | 533,687.00 |
| 2016 | |
| 2015 | 245,634.00 |
Download all data from 2003 to 2019
How does China rank in Re-Import of Heparin for Therapeutic Use?
| # | 9 Countries | US Dollars | Last | YoY | 5‑years CAGR | |
|---|---|---|---|---|---|---|
| 1 |
#1
Canada
|
1,738,281.50 | 2019 | +72.9 % | +112.5 % | View data |
| 2 |
#2
Australia
|
1,253,862.50 | 2019 | +10.8 % | +309.1 % | View data |
| 3 |
#3
China
|
676,088.00 | 2019 | -4.6 % | -3.9 % | View data |
| 4 |
#4
France
|
378,030.03 | 2019 | -14.2 % | -8.6 % | View data |
| 5 |
#5
Argentina
|
282,142.75 | 2019 | +110.6 % | -13.7 % | View data |